Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Retained Earnings (2016 - 2025)

Sangamo Therapeutics has reported Retained Earnings over the past 16 years, most recently at -$1.6 billion for Q4 2025.

  • Quarterly results put Retained Earnings at -$1.6 billion for Q4 2025, down 8.17% from a year ago — trailing twelve months through Dec 2025 was -$1.6 billion (down 8.17% YoY), and the annual figure for FY2025 was -$1.6 billion, down 8.17%.
  • Retained Earnings for Q4 2025 was -$1.6 billion at Sangamo Therapeutics, down from -$1.6 billion in the prior quarter.
  • Over the last five years, Retained Earnings for SGMO hit a ceiling of $2.0 million in Q2 2021 and a floor of -$1.6 billion in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$10.8 million (2022), compared with a mean of -$566.1 million.
  • Biggest five-year swings in Retained Earnings: skyrocketed 220.21% in 2021 and later tumbled 37546.93% in 2025.
  • Sangamo Therapeutics' Retained Earnings stood at -$4.0 million in 2021, then tumbled by 110.79% to -$8.4 million in 2022, then soared by 45.32% to -$4.6 million in 2023, then tumbled by 32638.13% to -$1.5 billion in 2024, then fell by 8.17% to -$1.6 billion in 2025.
  • The last three reported values for Retained Earnings were -$1.6 billion (Q4 2025), -$1.6 billion (Q3 2025), and -$1.5 million (Q2 2025) per Business Quant data.